McKesson said the board elected Deborah Dunsire, M.D. as a director, assigned her to the Compensation and Talent Committee and Finance Committee, and that her appointment is effective June 3, 2024. The effective date is May 31, 2024.

1. 01

   McKesson said the board elected Deborah Dunsire, M.D. as a director, assigned her to the Compensation and Talent Committee and Finance Committee, and that her appointment is effective June 3, 2024. The effective date is May 31, 2024.

2. 02

   The company said Dr. Dunsire has more than 30 years of experience leading organizations in the biopharmaceutical, oncology and other specialty industries, and that she served as president and chief executive officer of H. Lundbeck A/S from 2018 to 2023.

3. 03

   The company said Linda Mantia and Susan R. Salka will not stand for re-election at the 2024 annual meeting of shareholders, and their terms will expire at that meeting.

4. 04

   The company said in its news release that if all proposed director nominees are elected at the annual meeting, the board will be reduced to 11 members, of whom 10 will be independent.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.